Astemizole, a Second-Generation Histamine H1-Receptor Antagonist, Did Not Attenuate the Aggregation Process of α-Synuclein In Vitro.
Parkinson’s disease
amyloid
astemizole
synuclein
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
30
12
2023
revised:
03
03
2024
accepted:
05
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
The antihistamine astemizole has shown disease-modifying effects in several preclinical disease models of Parkinson's disease (PD). Astemizole also interacts with an anomalous aggregation of Alzheimer's disease-related amyloid-β (Aβ) peptide and has inhibitory activity on the human prion protein PrP
Identifiants
pubmed: 38540224
pii: biomedicines12030611
doi: 10.3390/biomedicines12030611
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ulsan University Hospital Research Grant
ID : UUH-2017-03
Organisme : National Research Foundation of Korea
ID : 2021R1F1A1062478